603102.SHG Weihai Baihe Biology Technological Co. Ltd.
- Market cap
- CNY 2.11B
- P/E
- 18.2x
- P/B
- 1.24x
- ROE
- 6.6%
- Dividend yield
- 2.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603102.SHG undervalued?
Graham number603102.SHG trades 0.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Weihai Baihe Biology Technological Co. Ltd. fundamental analysis
No fundamental analysis for Weihai Baihe Biology Technological Co. Ltd. yet.
Weihai Baihe Biology Technological Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Weihai Baihe Biology Technological Co. Ltd.
Weihai Baihe Biology Technological Co., Ltd., together with its subsidiary, Weihai Lily Functional Food Technology Research Institute Limited Company, research, develops, manufactures, and sells nutrition and health food products in China and internationally. The company offers health food; nutritious food for feminine glamour, male energy, elderly care, pregnancy, babies, and childcare, as well as nutritional soft candies; special diet products comprising supplementary food…
Full company profileWeihai Baihe Biology Technological Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Weihai Baihe Biology Technological Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 500M | 578M | 662M | 725M | 871M | 801M | 911M | 965M |
| Gross Profit | 204M | 253M | 275M | 264M | 326M | 292M | 322M | 343M |
| Operating Income | 96.7M | 152M | 168M | 149M | 183M | 148M | 150M | 158M |
| EBITDA | 101M | 155M | 193M | 191M | 231M | 202M | 199M | 145M |
| Net Income | 74.3M | 127M | 148M | 138M | 169M | 139M | 128M | 112M |
| EPS | 1.55 | 2.65 | 3.08 | 2.15 | 2.64 | 2.18 | 2.01 | 1.75 |
| Balance Sheet | ||||||||
| Total Assets | 620M | 731M | 916M | 1.66B | 1.74B | 1.82B | 1.96B | 1.97B |
| Total Liabilities | 157M | 151M | 202M | 240M | 222M | 210M | 269M | 250M |
| Shareholders' Equity | 463M | 580M | 714M | 1.42B | 1.51B | 1.61B | 1.66B | 1.69B |
| Cash & Short-term Investments | 292M | 385M | 414M | 1.10B | 1.14B | 1.13B | 1.14B | 1.10B |
| Cash Flow | ||||||||
| Operating Cash Flow | 121M | 150M | 169M | 153M | 194M | 128M | 186M | - |
| Capital Expenditure | 20.2M | 34.0M | 125M | 51.5M | 96.5M | 94.9M | 55.7M | 35.5M |
| Free Cash Flow | 101M | 116M | 44.6M | 101M | 97.3M | 32.7M | 130M | 76.5M |
| Ratios | ||||||||
| ROE | 16.1% | 21.9% | 20.7% | 9.7% | 11.2% | 8.7% | 7.8% | 6.6% |
| ROA | 12.0% | 17.4% | 16.2% | 8.3% | 9.7% | 7.7% | 6.6% | 5.7% |
| Net Profit Margin | 14.9% | 22.0% | 22.4% | 19.0% | 19.4% | 17.4% | 14.1% | 11.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Weihai Baihe Biology Technological Co. Ltd. dividends
- Dividend yield
- 2.21%
- Forward dividend
- 0.75 CNY
- Payout ratio
- 36.4%
- Ex-dividend date
- Aug 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 46.7M | 0.73 | 36.4% |
| 2024 | CNY 47.2M | 0.74 | 33.9% |
| 2023 | CNY 38.4M | 0.60 | 22.7% |
| 2022 | CNY 32.0M | 0.50 | 23.2% |
| 2021 | CNY 14.4M | 0.30 | 9.7% |
| 2020 | CNY 23.5M | 0.49 | 18.5% |
| 2019 | CNY 23.5M | 0.49 | 31.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Weihai Baihe Biology Technological Co. Ltd.
- Insiders 57.71%
- Institutions 3.58%
- Public & others 38.71%
- Shares outstanding 64.0M
- Free float 26.7M
Weihai Baihe Biology Technological Co. Ltd. company profile
- Company name
- Weihai Baihe Biology Technological Co. Ltd.
- Ticker
- 603102.SHG
- ISIN
- CNE100005RB6
- Exchange
- Shanghai Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 1,096
- Fiscal year end
- December
- Address
- No. 552, Chengda Road, Rongcheng, China, 264321
- Phone
- 86 40 0675 7818
- Website
- baiheshengwu.com
About Weihai Baihe Biology Technological Co. Ltd.
Weihai Baihe Biology Technological Co., Ltd., together with its subsidiary, Weihai Lily Functional Food Technology Research Institute Limited Company, research, develops, manufactures, and sells nutrition and health food products in China and internationally. The company offers health food; nutritious food for feminine glamour, male energy, elderly care, pregnancy, babies, and childcare, as well as nutritional soft candies; special diet products comprising supplementary food and nutritional supplements, nutritional supplements for pregnant women and lactating mothers, and sports nutrition supplements; and official approval services for health food declarations, as well as produces and sells pet food. It provides its products in the form of soft and hard capsules, tablets, powders, oral liquids, drops, and bottled and bagged beverages. The company sells its products under the Biohek, Hongyangshen, Yunyangyan, Forzal, Zulixing, and Nengbeijian brands. It also exports its products to approximately 70 countries, including Europe and the United States. Weihai Baihe Biology Technological Co., Ltd. was founded in 1996 and is headquartered in Rongcheng, China.
Weihai Baihe Biology Technological Co. Ltd. management
7- Mr. Xinli LiuGM & Chairman of the Board · born 1962
- Mr. Dong Dong TangFinancial Director · born 1983
- Mr. Wentong WangDeputy GM & Director · born 1973
- Ms. Lina WangDeputy GM & Director · born 1981
- Mr. Haitao LiuDeputy GM & Director · born 1977
- Mr. Tongbo SunBoard Secretary · born 1971
- Xin Zhi LiuAccounting Supervisor